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The prion protein family member 
Shadoo induces spontaneous ionic 
currents in cultured cells
Antal Nyeste1,2,*, Claudia Stincardini3,*, Petra Bencsura2, Milica Cerovic4, Emiliano Biasini3,4 & 
Ervin Welker1,2
Some mutant forms of the cellular prion protein (PrPC) carrying artificial deletions or point mutations 
associated with familial human prion diseases are capable of inducing spontaneous ionic currents 
across the cell membrane, conferring hypersensitivity to certain antibiotics to a wide range of cultured 
cells and primary cerebellar granular neurons (CGNs). These effects are abrogated when the wild type 
(WT) form is co-expressed, suggesting that they might be related to a physiological activity of PrPC. 
Interestingly, the prion protein family member Shadoo (Sho) makes cells hypersensitive to the same 
antibiotics as mutant PrP-s, an effect that is diminished by the co-expression of WT-PrP. Here, we report 
that Sho engages in another mutant PrP-like activity: it spontaneously induces large ionic currents in 
cultured SH-SY5Y cells, as detected by whole-cell patch clamping. These currents are also decreased by 
the co-expression of WT-PrP. Furthermore, deletion of the N-terminal (RXXX)8 motif of Sho, mutation 
of the eight arginine residues of this motif to glutamines, or replacement of the hydrophobic domain by 
that of PrP, also diminish Sho-induced ionic currents. Our results suggest that the channel activity that 
is also characteristic to some pathogenic PrP mutants may be linked to a physiological function of Sho.
A great deal of evidence indicates that the prion protein (PrPC), encoded by the prnp gene, is involved in several 
neurodegenerative disorders, including Creutzfeldt-Jacob disease, Gerstmann-Sträussler-Scheinker syndrome, 
fatal familial insomnia, kuru, and possibly Alzheimer’s disease. These pathological conditions are characterized 
by protein aggregation and formation of β -sheet rich amyloid deposits, which might use PrPC to deliver toxic 
signals1–8. However, the mechanism by which PrPC transduces these signals is still not clear9–11. In this respect, a 
deeper understanding of the biology of the prion family proteins is essential for deciphering their complex inter-
action networks12,13 and for identifying those processes that are indeed involved in the above disorders.
Mutant forms of PrP carrying point mutations or deletions in the central region (CR, amino acid residues 
105 through 125 in murine PrP) of the protein have provided a great deal of information regarding the potential 
toxic processes involving prion proteins14–17. A large part of data have been obtained with a mutant lacking the 
entire central region (referred to as Δ CR-PrP); transgenic mice expressing this mutant form [Tg(Δ CR)] on a 
prnp-null background exhibit neonatal lethality, massive spontaneous degeneration of cerebellar granule neu-
rons (CGNs), and white matter pathology in the brain and spinal cord18. When Tg(Δ CR) mice are crossed with 
WT-PrP expressing mice, the phenotype is dose-dependently suppressed by the presence of the WT protein, 
expanding the lifespan from few weeks to more than 1 year when a five-fold excess is established. This suggests 
that WT-PrP and Δ CR-PrP act on the same molecular pathway, or else, that these two forms may physically inter-
act19. Although the toxicity of Δ CR-PrP is not evident when using immortalized cells, Massignan et al. revealed 
that cells expressing this mutant form are hypersensitive to two classes of antibiotics, aminoglycosides and bleo-
mycin analogues20. Interestingly, the co-expression of WT-PrP diminishes this hypersensitivity. Additional stud-
ies employing electrophysiology on Δ CR-PrP-expressing cells detected the presence of spontaneous large ionic 
currents in several kinds of immortalized cells21, primary neuronal cultures and cerebellar slices22. Again, the 
co-expression of WT-PrP silences these currents.
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Further insights came from studies investigating two other members of the prion protein family12: doppel, a 
neurotoxic protein sharing structural similarities with the C-terminal globular fold of PrPC 23, and Sho, a natively 
disordered protein displaying structural features similar to the N-terminal, flexible tail of PrPC 24. Interestingly, 
the latter has been shown to possess WT-PrP-like protective properties, as its expression suppresses the toxicity 
of doppel and PrPΔ 32-121, proteins that display Δ CR-PrP-like toxic effects25. Even more, when the hydropho-
bic domain (HD, amino acid residues 62 through 77 in murine Sho) - the only part of Sho bearing considerable 
sequence similarity with PrPC - was deleted, these protective effects were no longer detectable. By contrast, when 
expressed in cultured immortalized cells (SH-SY5Y and HEK293) Sho expression caused hypersensitivity to 
Zeocin or G418, in a dose dependent manner, mimicking the expression of the Δ CR-PrP mutant. This phenotype 
was also rescued by the co-expression of WT-PrP26. All together, these data indicate that PrPC and Sho may act on 
the same cellular pathways, via similar mechanisms.
In this study we describe a structural-functional characterization of the sequence determinants of Sho-induced 
cellular hypersensitivity to G418. Importantly, we also report that, similarly to Δ CR-PrP, Sho spontaneously 
induces ionic currents across the plasma membrane, as detected by patch clamping experiments.
Results
The role of the (RXXX)8 motif in the drug sensitizing activity of Sho. In order to display a toxic 
effect, Δ CR-PrP requires an intact PB1 domain (amino acid residues 23 through 27), a positively charged short 
segment17,27–29. This domain is also essential for the protective activities of WT-PrP30. In order to examine 
whether the N-terminal domain of Sho [(RXXX)8 motif31] is also essential for its drug-sensitizing activity26, we 
engineered a mutant Sho protein construct lacking amino acids 25 through 61 [ShoΔ (RXXX)8] (Fig. 1). Using 
an expression system employed previously for the expression of WT-Sho in SH-SY5Y cells, which harbour no 
detectable amount of endogenous Sho26, we developed cells stably expressing this deletion-mutant. Both WT and 
mutant Sho correctly localize at the cell surface, being attached to the plasma membrane via glycosylphosphati-
dylinositol (GPI) anchors (Fig. 2a and Supplementary Fig. S2) and are N-glycosylated (Fig. 2b). The mobility shift 
caused by the deletion of the (RXXX)8 motif is detectable when the protein is deglycosylated (Fig. 2b) as a result 
of peptide N-glycosidase F (PNGaseF) treatment. The expression level of the Δ (RXXX)8 mutant Sho protein in 
the cells is higher than that of the WT-Sho (Fig. 2a and Supplementary Fig. S3). The presence of the WT-Sho 
protein causes SH-SY5Y cells to be hypersensitive to G418 treatment i.e.: a considerable decrease in the viability 
of the cells is apparent at drug concentrations where the control SH-SY5Y cells seem to be unaffected. Despite the 
Figure 1. PrP and Sho constructs used in the studies. Schemes of the polypeptide chains indicate the domain 
structures and features of interest. α A, α B, α C: alpha helices. Narrow, tall, dark green boxes: β -strands. CHO: 
N-glycosylation sites. GPI: GPI-anchors. Blue brackets: disulphide bonds. Striated boxes: polybasic regions (PB1 
(blue), PB2 (white) in PrP, (RXXX)8 in Sho), whereas, the non-striated blue boxes in Sho(QXXX)8 construct 
indicate the (QXXX)8 region. Red boxes in PrP: octarepeat region (OR). Yellow and orange boxes: hydrophobic 
domains (HD) of PrP or Shadoo, respectively. Numbers indicate the last and first residues neighbouring the 
deletions. Green tones: structured region of PrP.
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higher abundance, the presence of the Δ (RXXX)8 mutant does not confer a drug-sensitizing phenotype to the 
cells. To see if the positively-charged amino acids are indeed the critical determinants of the toxicity-associated 
Sho phenotype, we mutated all eight arginines of the (RXXX)8 motif to glutamines (Fig. 1). This mutant protein 
[Sho(QXXX)8] is processed by the cells like WT-Sho, as assessed by phosphatidylinositol-dependent phospho-
lipase C (PI-PLC) and PNGaseF treatment combined with western blot, and reaches expression levels higher 
than that of WT-Sho (Fig. 2a,b, and Supplementary Fig. S3). Nevertheless, no significant differences are discern-
ible when these cells are compared to the control SH-SY5Y, or to the deletion mutant [ShoΔ (RXXX)8] protein 
expressing ones in a G418 viability assay (see Fig. 2c,d). These results indicate a critical role for the (RXXX)8 motif 
of Sho in the observed drug hypersensitivity phenotype.
The role of the hydrophobic domain in the drug sensitizing activity of Sho. The hydrophobic 
domains, the part of PrPC and Sho that share more extended sequence similarity, have considerable influence 
Figure 2. The presence of the (RXXX)8 domain is necessary for the drug sensitizing activity of the Sho 
protein. (a) Western blot analysis of the (RXXX)8 domain mutant Sho constructs’ cell surface localization. Cell 
lysates from mCherry, Sho, ShoΔ (RXXX)8 and Sho(QXXX)8 expressing SH-SY5Y cells, incubated with (+ ) or 
without (− ) PI-PLC are tested (upper left panel). On the upper right panel lanes of mCherry and Sho expressing 
SH-SY5Y cells of the same membrane after longer exposure are shown. β -actin was used as loading control 
(lower panel). Immunoblotting of the respective medium supernatants for the presence of Sho is presented in 
Supplementary Fig. S2. (b) Western blot analysis of (RXXX)8 domain mutant Sho constructs’ N-glycosylation in 
lysates of mCherry, Sho, ShoΔ (RXXX)8 and Sho(QXXX)8 expressing SH-SY5Y cells, treated (+ ) or not treated 
(− ) by PNGaseF. On the upper right panel lanes of mCherry and Sho expressing SH-SY5Y cells of the same 
membrane after longer exposure are shown. Empty and filled arrowheads mark the full length Shadoo and the 
C1 fragment, respectively. β -actin was used as loading control (lower panel). (a,b) *: marks nonspecific bands. 
Numbers and marks on the left indicate the positions of the corresponding molecular-weight size markers in 
kDa. Cropped images of immunoblots. Full length blots are presented in Supplementary Fig. S4. (c,d) Δ (RXXX)8 
or (QXXX)8 mutations interfere with G418 hypersensitivity caused by the WT-Sho in SH-SY5Y cells (48 hours 
treatment). 100% is the fluorescence value of untreated control of each cell line. (c) Cytotoxicity assay, using 
PrestoBlue reagent: representative experiment carried out at G418 concentrations between 0 and 1000 μ g/ml on 
various cells, as indicated. Values are means ± S.D. of corresponding replicas within the experiment. (d) Bars show 
the means ± S.D. of cell viabilities measured at 250 μ g/ml G418 concentration in n = 3 independent experiments. 
Samples were compared to non-transfected SH-SY5Y cells, ***p < 0.001.
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on the toxic/protective phenotypes of PrPC 32 and Sho33. To assess its role in the drug hypersensitising pheno-
types conferred by Sho expression, we deleted Sho’s HD (amino acid residues 62 through 77; ShoΔ HD, Fig. 1) 
and expressed the mutant protein in SH-SY5Y cells. Figure 3a,b shows that ShoΔ HD is on the cell surface and 
is N-glycosylated, respectively, although its expression reaches much lower level than that of the WT protein 
(Fig. 3a, and Supplementary Fig. S3). Since the epitope of the anti Sho antibody used in this experiment lies out-
side of the deleted region, it is unlikely that the weaker signals of ShoΔ HD on the blot are related to an altered 
affinity of the antibody to the mutant Sho protein. The deletion of HD does not diminish the ability of Sho to 
cause G418 hypersensitivity to cells (Fig. 3e,f). Considering the much lower expression level of ShoΔ HD (at a 
similar level WT-Sho exhibits only reduced activity26), it is likely that ShoΔ HD is more effective to induce this 
phenotype than WT-Sho. While these experiments suggest that the presence of Sho’s HD is not required for con-
ferring drug hypersensitivity, its absence seems to aggravate it.
To clarify the importance of this region of PrP in the drug hypersensitivity phenotype, we replaced the HD 
of Sho with that of PrPC [amino acid residues 111 through 133; Sho(PrPHD), Fig. 1]. Figure 3c,d shows that this 
mutant also localizes on the cell surface and is glycosylated in SH-SY5Y, respectively. Even though the expres-
sion level of this mutant was higher than that of WT-Sho, the presence of the HD segment of PrPC greatly sup-
pressed the drug-sensitizing effect of Sho, although, at higher G418 concentrations the effect was still detectable 
(Fig. 3e,f).
Sho causes spontaneous ionic currents in two different cell lines. It was previously reported that 
Δ CR-PrP, as well as other mutant PrP forms carrying deletions or disease-associated point mutations in the 
central region, can induce spontaneous ionic currents in cultured cells and primary neurons21. Similarly to the 
drug-hypersensitizing effect, these currents are abrogated by the co-expression of WT-PrP. To assess whether Sho 
can also induce similar currents, we carried out patch clamp experiments on SH-SY5Y cells expressing either 
WT-Sho or different Sho mutants (Fig. 4). We found that expression of Sho induces Δ CR-PrP-like ionic currents, 
even though the size, frequency and duration of these bursts are generally of lower magnitude as compared to 
Δ CR-PrP (Fig. 4a). As a possible result of the currents, we also detected a significant alteration in resting mem-
brane potentials in Sho-expressing cells, as compared to controls [the measured resting membrane potentials 
were as follow: non-transfected SH-SY5Y: 44 ± 3 mV; GFP-expressing cells: 38 ± 4 mV; mCherry-expressing cells: 
37 ± 5 mV; PrP ∆ CR-expressing cells: 24 ± 2 mV; Sho-expressing cells: 28 ± 3 mV; Sho + GFP-expressing cells: 
28 ± 4; PrP WT-expressing cells: 39 ± 5 mV; Sho + PrP-expressing cells: 41 ± 4 mV; Sho(QXXX)8-expressing cells: 
40 ± 6 mV; Sho(PrPHD)-expressing cells: 38 ± 4 mV; Sho ∆ H-expressing cells: 30 ± 3 mV]. Importantly, we also 
observed that co-expression of WT-PrP silences Sho-associated currents. Both Sho-induced currents and the 
PrP’s silencing activity were observed also in HEK293 cells (Fig. 5). This observation indicates that, as reported 
previously for Δ CR-PrP, both effects apparently occur independent of the cell line in which the proteins are 
expressed. Moreover, mutation of the arginine residues within the (RXXX)8 motif to glutamines abolishes the 
current-inducing abilities of Sho, while deletion of the HD had no such effects. Interestingly, replacement of the 
HD of Sho with that of PrP silenced these Sho-induced currents (Fig. 4b). Collectively, these results demonstrate 
that Sho is capable of inducing spontaneous ionic currents at the cell membrane, mimicking the channel activity 
of toxic PrP mutants.
Discussion
The most significant finding of these studies is that Sho expression spontaneously generates ionic currents similar 
to those induced by Δ CR-PrP and other disease-associated PrP mutants.
Several evidences suggest that the nature of the Sho-induced currents is similar or even identical to that 
induced by Δ CR-PrP. Both currents are highly irregular, fluctuating randomly over a time course of seconds to 
minutes, and reaching amplitudes of several thousand pA. Furthermore, co-expression of WT-PrP silences the 
currents in both cases. In addition, the replacement of the HD in the sequence of Sho with the HD of the prion 
protein also diminishes these currents, suggesting that identical roles are played or undertaken by PrP HD in 
case of both proteins and both processes. Another parallel between Sho and mutant PrP-s is their ability to con-
fer drug hypersensitivity, as revealed by G418 treatment and viability assays. Consistent with the data collected 
with Δ CR-PrP, WT and mutant variants of Sho reveal a nearly perfect correlation between the induction of drug 
hypersensitivity and the channel activity, with some mutants either causing both ionic currents and drug hyper-
sensitivity (Sho, ShoΔ HD), or neither of them [ShoΔ (RXXX)8, and Sho(QXXX)8]. These results support the idea 
that the two phenotypes are intrinsically linked, with the drug hypersensitivity being a secondary effect of the 
inability of the cells to maintain ion homeostasis, affecting drug uptake32.
The molecular basis of the observed ionic currents is still not clear. The fact that Sho induces very similar 
currents to that of Δ CR-PrP challenges many of the previous interpretations.
It has been proposed that Δ CR-PrP molecules themselves may form cationic channels or pores in the cell 
membrane by the transient self-associations of PrP molecules16,32. WT-PrP molecules might also associate on 
the cell surface, however, without resulting in cationic permeable channels or pores. Previous studies speculated 
that one potential mechanism for this might be a transient electrostatic interaction between the N-terminal and 
the globular part34,35, that may physiologically be present in WT-PrP, and that is hindered from taking place in 
the absence of the CR (residues 105 through 125, also called hinge region), leaving the N-terminal free and able 
to penetrate the plasma membrane. The possibility that Sho would also be able to self-associate to form pores 
remains to be investigated.
Another interpretation is that Sho, like Δ CR-PrP may directly modulate the activities of specific ion channels 
either by interacting with them or by indirectly regulating their activity. While PrPC has been suggested to influ-
ence the activity of several ion channels36,37 in case of Sho such an activity needs to be verified.
www.nature.com/scientificreports/
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Figure 3. The hydrophobic domain (HD) of the Sho protein is not necessary for the drug sensitizing activity 
but modulates it. (a) Western blot analysis of Δ HD mutant Sho construct’s cell surface localization. Cell lysates 
from mCherry, Sho and ShoΔ HD expressing SH-SY5Y cells, incubated with (+ ) or without (−) PI-PLC are 
tested (upper panel). (b) Western blot analysis of Sho N-glycosylation in lysates of the indicated cells, treated (+) 
or not treated (− ) with PNGaseF (upper left panel). On the upper right panel lanes of mCherry and ShoΔHD 
expressing SH-SY5Y cells of the same membrane after longer exposure are shown. (c) Western blot analysis of 
Sho(PrPHD) construct’s cell surface localization. Cell lysates from mCherry, Sho and Sho(PrPHD) expressing 
SH-SY5Y cells, incubated with (+ ) or without (− ) PI-PLC are tested (upper panel). (d) Western blot analysis 
of Sho N-glycosylation in lysates of the indicated cells, treated (+ ) or not treated (− ) with PNGaseF (upper left 
panel). On the upper right panel lanes of mCherry and Sho expressing SH-SY5Y cells of the same membrane 
after longer exposure are shown. (a–d) *Marks a nonspecific band. Numbers and marks on the left indicate the 
positions of the corresponding molecular size markers in kDa. An intracellular protein, β -actin was used as 
loading control for cell lysates (lower panels). Cropped images of immunoblots. Full length blots are presented 
in Supplementary Fig. S4. (e,f) Deletion of HD (ShoΔ HD) doesn’t interfere with G418 hypersensitivity caused 
by Sho in SH-SY5Y cells (48 hours treatment), but replacement of Sho HD with PrP HD [Sho(PrPHD)] reduces 
this effect. 100% is the fluorescence value of untreated control of each cell line. Sho(QXXX)8 construct was used 
as non-sensitizing negative control. (e) Cytotoxicity assay, using PrestoBlue reagent: representative experiment 
carried out at G418 concentrations between 0 and 1000 μ g/ml on various cells, as indicated. Values are 
means ± S.D. of corresponding replicas within the experiment. (f) Bars show the means ± S.D. of cell viabilities 
measured at 250 μ g/ml G418 concentration in n = 3 independent experiments. Samples were compared to SH/
Sho(QXXX)8 cells, ***p < 0.001.
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Our experiments might provide further insights into this process. We found that the deletion of the HD nei-
ther has an effect on ionic currents, nor diminishes the drug hypersensitizing ability of Sho. By contrast, insert-
ing the HD of PrPC to replace Sho’s HD diminishes both phenotypes. Since the presence of this domain is also 
required in WT-PrP to suppress the same activities, PrP HD seems to have a critical role in these processes, likely 
more than just functioning as a hinge and connecting the N- and C-terminus of PrP, as previously proposed16.
We found that the presence of the (RXXX)8 motif31 is essential for Sho to induce ionic currents or drug hyper-
sensitivity; this could indicate either a direct or an indirect effect. Since the mutant Sho protein is correctly local-
ised on the cell surface and altering only the positively charged character of the (RXXX)8 motif is sufficient to 
diminish the ionic currents and G418 hypersensitizing ability of Sho, it is more likely that the arginines of the 
(RXXX)8 motif themselves are involved in some interactions critical for this phenotype.
Figure 4. Sho protein, akin to PrPΔCR induces inward ionic currents. (a) Representative traces of whole 
cell patch clamp recordings on SH-SY5Y cells non-transfected or expressing the indicated proteins: wild-type or 
mutant Sho or PrP, or the empty vectors (possessing EGFP or mCherry expression reporter) at holding potential 
of − 80 mV. (b) Current activity recorded in the different types of SH-SY5Y cell clones, plotted as percentage of 
total time the cells exhibited inward currents ≥ 200 pA. (Mean ± SEM; SH-SY5Y: no currents detected; GFP: no 
currents detected; mCherry: 0.3 ± 0.1; PrP∆ CR: 45.4 ± 9.4; Sho + mCherry: 14.9 ± 4.9; Sho + GFP: 18.5 ± 0.1; 
PrP: no currents detected; Sho + PrP: 2.0 ± 0.01; 307: 0.46 ± 0.01; 309–250: 0.54 ± 0.0; 324–200: 11.67 ± 0.05). 
In brackets the number of samples for each cell type is indicated. Of note, in approximately 25% of PrP∆ CR or 
Sho cells, recordings lasted less than 2 min. These data, which may reflect an intrinsic cell fragility, were omitted 
from the analyses.
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What is the nature of these interactions? One possible interpretation can be drawn from the analogy with the 
corresponding PrP region: The positively charged N-terminal KKRPK sequence (the first polybasic domain: PB1) 
was shown to function as a protein transduction domain, capable of aberrantly inserting the adjacent polypep-
tide segments through the lipid bilayer, giving rise to the observed currents27,32,38. In the frame of this scenario, 
Sho might form transient pores as well, and its positively charged N-terminus could possess similar transducing 
capabilities. Indeed, the (RXXX)8 motif resembles an α -helical amphipathic model peptide with transducing 
capacities: KLALKLALKALKAALKL39. Thus, although this conclusion still needs proof, it is tempting to spec-
ulate that the positively charged regions of PrPC and Sho may share protein transducing characteristics, being 
able to penetrate and traverse the membrane, pulling a segment of the disordered polypeptide chains through 
the lipid bilayer. The hydrophobic domain of PrPC might behave like transmembrane helices and may stabi-
lize this transduced structure by positioning itself at a stable orientation across the membrane. The transduced 
Figure 5. Sho protein expressed in HEK293 cell line induces inward ionic currents. (a) Representative 
traces of whole cell patch clamp recordings on HEK293 cells expressing mCherry only or the wild-type Sho, as 
well as co-expressing Sho and GFP or PrP at holding potential of − 80 mV. (b) Current activity recorded in the 
different types of HEK293 cells, plotted as percentage of total time the cells exhibited inward currents ≥ 200 pA. 
(Mean ± SEM; mCherry: no currents detected; Sho: 17.8 ± 4.1; Sho + GFP: 22.0 ± 6.4; Sho + PrP: 4.4 ± 2.4). The 
number of recorded cells for each type is indicated in brackets.
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polypeptide chains may or may not associate in the membrane by these regions, but in either case they result in 
no ionic currents. Being fully hydrophobic, even if they associate, HD-s cannot form membrane channels with 
polar residues facing inside that would allow exchange of polar molecules between the outside and the cell inte-
rior. The polybasic region between amino acid residues 100 and 109 (PB2, in murine PrP) may help to position 
the HD into the membrane bilayer; its deletion also induces currents16. In the absence of the HD the hydrophilic 
polypeptide segments of Δ CR-PrP molecules that are pulled into the lipid bilayer are forced to be stuck together 
to minimise contact with the hydrophobic core of the lipid bilayer and are disrupting the membrane integrity 
forming hydrophilic pores that are permeable for ions. The absence of transmembrane segments may render an 
unstable dynamic character to the transduced structure explaining the highly irregular nature of the currents. The 
drug hypersensitivity might be a secondary effect induced by the altered ion balance resulted from the formation 
of these pores. The Sho HD being shorter might not be able to stabilise itself in the membrane in a similar manner, 
thus, the protein may show the same phenotype as the deletion mutant PrP-s.
WT-PrP, when present, disrupts Δ CR-PrP and Sho channels. The rescue by WT-PrP calls for additional 
details to be added to this model, such as the interaction of WT-PrP with mutant prion proteins, and with Sho. In 
support of this model, a direct in vivo (and in vitro) interaction between PrPC and Sho has been suggested by a few 
studies13,40. However, these associations cannot be mediated by an interaction between the HD-s41, since the HD 
is not present in some toxic mutant variants.
Obviously, other proteins could contribute to the formation of mutant PrP- and Sho-induced channels. The 
effects found with point mutations in the central region of PrP21 present additional challenge to this model. The 
mutations (P101L, G113V, and G130V) do not change much the hydrophobic character of the region but still 
induce channel activity and drug hypersensitivity, indicating that the HD needs additional structural require-
ments than just the hydrophobic character for stabilising a structure where the transduced polypeptides are 
merged in the lipid bilayer and positioned with their hydrophobic segments.
In the alternative model, PrP interacts with an ion channel complex in a dual mode: binding of the C-terminal 
globular domain of PrP to the complex is potentiated by the polybasic region of PrP (PB1). This binding causes 
dysfunction of the channel showing unregulated opening and triggering the detected toxic signals, an effect that 
is attenuated by the binding of the N-terminal parts involving the HD to a second site. In the lack of the first 
polybasic region, the C-terminal domain does not bind to the complex. Deletion or alteration of the HD blocks 
its proper binding to the second site of the channel complex resulting in spontaneous ionic currents. Depending 
on the structural alteration caused by each mutation, PrP mutants may show decreased ability to induce ionic 
currents in parallel with a less severe in vivo phenotype. WT-PrP would compete for both binding sites, rescuing 
the detrimental effects of each mutant. It can be envisaged that Sho also interacts with such complex to induce 
spontaneous currents. However, since, no interaction of Sho with ion channels has been reported so far, this 
possibility remains to be proven.
Prion protein exhibits dual activity, with the WT protein displaying protective phenotypes while some mutant 
variants with internal deletions are being involved in toxic processes2. Interestingly, in case of Sho the WT protein 
is the one that itself exerts either protective or toxic activities depending on the experimental paradigms exam-
ined25,26,40. However, none of the phenotypes of Sho-expressing cells seen in vitro, protective or toxic, are apparent 
in vivo. One would expect that if the protective activity of Sho seen in vitro prevails in vivo this effect should be 
apparent in Tg(Δ CR) mice where the presence of WT-PrP does not mask this protective activity. Although, 
in lack of universal anti-Sho antibodies it might not be trivial to gain clear distinction between expressing and 
non-expressing tissues; using a combinations of three anti-Sho antibodies it has been argued that the reason why 
Sho does not manifest a protective role in Tg(Δ CR) mice is due to a lack of its expression in CGNs25. PrPC has 
been shown to be able to perform its protective activities in trans42,43. It would be also interesting to know if Sho 
can exert its protective effects in trans, and, if the glial cells of the region have any Sho expression, which should 
provide protection to Tg(Δ CR) mice CGNs in the lack of Sho expression in CGNs themselves. By contrast, if 
in vivo Sho is involved in toxic activities, such as observed in vitro, this should be apparent in prnp-null mice 
where the co-expression of the endogenous PrP does not diminish this effect. In the absence of such effects 
that are apparent in the Shmerling14 and Tg(Δ CR)18 mutant mice, it is also speculated that the endogenous Sho 
expression level might be much lower than that of PrP, that is simply too low for displaying a toxic effect in 
prnp-null mice26. Crossing of Sho over-expressing mice with prnp-null or Tg(Δ CR) mice could clarify the second 
as well as the first issue, respectively.
Methods
Chemicals, reagents, antibodies. Restriction endonucleases, T4 DNA ligase and Pfu DNA polymer-
ase were purchased from Thermo Fisher Scientific. DNA oligonucleotides were from Microsynth AG (http://
microsynth.ch). High-glucose Dulbecco’s Modified Eagle Medium (DMEM) and fetal bovine serum (FBS) were 
obtained from Thermo Fisher Scientific (Gibco) and Penicillin/Streptomycin from Lonza. Proteinase inhibitor 
cocktail, Calpain inhibitor I, G418 were obtained from Sigma-Aldrich. Bradford-reagent was from Bio-Rad. 
Polyvinylidene fluoride (PVDF) transfer membrane and chemiluminescent substrate (Immobilon ECL sub-
strate) were from Millipore. PNGaseF was purchased from New England Biolabs. Phosphatidylinositol dependent 
phospholipase C (PI-PLC), and PrestoBlue reagent were obtained from Thermo Fisher Scientific. The following 
primary antibodies were used: anti-Sho rabbit polyclonal antibody (Abgent, AP4754b), anti-β -actin mouse mon-
oclonal antibody (Sigma, A1978). Secondary antibodies used were: Horseradish peroxidase (HRP)-conjugated 
anti-mouse and anti-rabbit IgG were from Jackson ImmunoResearch (715-035-151) and Pierce Biotechnology 
(31460), respectively. All other reagents and chemicals were purchased from Sigma-Aldrich.
Plasmid constructs and DNA cloning. The Sleeping Beauty and pRRL vectors containing EGFP, PrP, 
PrPΔ CR, mCherry, or Sho expression cassettes (see Table 1) were prepared earlier and are described in ref. 26.
www.nature.com/scientificreports/
9Scientific RepoRts | 6:36441 | DOI: 10.1038/srep36441
Preparation of LV/ShoΔ (RXXX)8(R) and LV/Sho(QXXX)8(R) plasmid vectors were carried out briefly, as fol-
lows. The plasmids encoding either ShoΔ 25–61 [ShoΔ (RXXX)8] or Sho(QXXX)8 were prepared earlier and are 
described in ref. 31. The DNA fragments harbouring the Δ (RXXX)8 and (QXXX)8 mutations in Sho cDNA were 
cut from the respective plasmids by NdeI and Eco81I restriction enzymes and were inserted between the same 
restriction sites of the LV/Sho(R) plasmid, replacing WT Sho cDNA with the deletion mutant constructs.
Preparation of LV/ShoΔ HD(R) plasmid vector was carried out briefly, as follows. The Sho HD (amino acid 
residues 62 through 71) was deleted by using QuikChange site directed mutagenesis and the following mutagen-
esis primers: ShoΔ HD-fwd and ShoΔ HD-rev. The DNA fragment encoding a CMV-IE promoter followed by 
the ShoΔ HD cDNA was amplified by PCR with the following PCR primers: V-Δ HD-fwd and V-Δ HD-rev. The 
amplified DNA product containing ShoΔ HD coding sequence was digested and inserted between the NdeI and 
SapI sites of the LV/Sho(R) vector, replacing WT Sho cDNA.
Preparation of LV/Sho(PrPHD)(R) plasmid vector. The HD in Sho cDNA was replaced by the HD of PrP briefly, 
as follows. The DNA linker (oligos PrPHDlin-fwd and PrPHDlin-rev) encoding mPrP HD (amino acid resi-
dues 111 through 133) was ligated between two PCR products, one harbouring a CMV-promoter followed by a 
Kozak-sequence and an 5′ fragment of the mSho cDNA (encoding amino acid residues 1 through 61) and another 
fragment harbouring a 3′ fragment of the mSho cDNA (encoding amino acid residues 78 through 147). The 
PCR products encoding the N and C-terminal Sho fragments were amplified from the LV/Sho(R) vector using 
the following primers: V-CMV-PrP-fwd and Sho-HD5-rev (N-terminal fragment) and Sho-HD3-fwd + V-ins-rev 
(C-terminal fragment) and were digested by the restriction enzyme BsmBI, producing a 5′ TCGC overhang on 
the 3′ side of the 5′ -fragment and a 5′ GGCC overhang on the 5′ end of the 3′ -fragment. The ligation of the two 
fragments and the linker was followed by the PCR amplification of the full DNA sequence encoding the chi-
meric protein Sho(1–61)-PrP(111–133)-Sho(78–147) [will be called further as Sho(PrPHD)] with the following 
primers: CMV-in-fwd and V-CMV-PrP-rev. The amplified DNA fragment encoding the chimeric Sho(PrPHD) 
was digested and inserted between NdeI and ApaI restriction sites of the LV/Sho(R) plasmid, replacing WT Sho 
cDNA.
Sequence correctness for the expression cassettes in all plasmids generated in this study was confirmed by 
Sanger sequencing (Microsynth AG).
Figure 1 summarizes the constructs (PrP and Sho) used in this study. DNA oligonucleotide sequences used for 
cloning are available in Supplementary Table S1.
Cell lines, culturing, transfection and transduction. The maintenance, transfection or transduction 
of SH-SY5Y human neuroblastoma cell line (ATCC CRL-2266TM) was carried out as described in ref. 26. The 
Shadoo-expressing and control transgenic HEK293 cell lines used in this study (Table 1) were established ear-
lier and are described in ref. 26. The lentiviruses were generated in the Hungarian National Blood Transfusion 
Service’s lentiviral facility.
All types of cells were regularly tested for mycoplasma contamination. EGFP and mCherry positivity were 
examined at every passage and experiments were carried out on cultures in which at least 90% of the cells 
expressed the required fluorescent markers. In parallel with the execution of the experiments, the expression lev-
els of the transgenes were determined by immunoblotting technique. Table 1 lists the cell types used in this study.
Immunoblotting. Cells seeded on 100 mm cell culture dishes were harvested at 70–90% confluence by wash-
ing once with PBS and scraping in 1 ml PBS. Harvested cells were pelleted by centrifugation (3 min, 200 × g) and 
re-suspended in ice cold lysis-buffer (50 mM HEPES, pH 7.5, 0.2 mM EDTA, 10 mM NaF, 250 mM NaCl, 0.5% 
NP-40, with 1% Proteinase inhibitor cocktail, 1% Calpain inhibitor, 1 mM DTT). The total protein concentration 
was measured by using Bradford protein assay. Where needed, PNGaseF treatment was carried out on samples 
of 20 μ g total protein, according to the manufacturer’s protocol. Samples of 20 μ g total protein, depending on the 
Name of transgenic cells Introduced transgenes Parental cell Vector used
SH/GFP* EGFP SH-SY5Y SB/GFP*
SH/PrP* mPrP and EGFP SH-SY5Y SB/PrP*
SH/PrPΔ CR* mPrPΔ (105–125) and EGFP SH-SY5Y SB/Δ CR*
SH/mCherry* mCherry SH-SY5Y LV/mCh*
SH/Sho* mSho and mCherry SH-SY5Y LV/Sho(R)*
SH/Sho + PrP* mPrP and EGFP SH/Sho LV/PrP(G)*
SH/ShoΔ (RXXX)8 mShoΔ (25–61) and mCherry SH-SY5Y LV/ShoΔ (RXXX)8(R)
SH/Sho(QXXX)8 mSho(QXXX)8 and mCherry SH-SY5Y LV/Sho(QXXX)8(R)
SH/ShoΔ HD mShoΔ (62–77) and mCherry SH-SY5Y LV/ShoΔ HD(R)
SH/Sho(PrPHD) Sho(1–61)-PrP(111–133)-Sho(78–147) and mCherry SH-SY5Y LV/Sho(PrPHD)(R)
HEK/mCherry* mCherry HEK293 LV/mCh*
HEK/Sho* mSho and mCherry HEK293 LV/Sho(R)*
HEK/Sho + GFP* EGFP HEK/Sho LV/GFP*
HEK/Sho + PrP* mPrP and EGFP HEK/Sho LV/PrP(G)*
Table 1. Cells with stable transgene expression used in these studies. Cell cultures and plasmid vectors 
marked with asterisks are described in ref. 26.
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necessities of the experiment, were run on 15% denaturing polyacrylamide gels and were blotted onto activated 
PVDF membrane, using a wet blotting system from Bio-Rad. The membrane was blocked for at least 1 hour in Tris 
buffered saline with Tween 20 (TBST), containing 5% nonfat milk powder, and primary antibodies were applied 
overnight, at 4 °C at the following dilutions: anti-Sho rabbit polyclonal antibody 1:200, anti-β -actin mouse mono-
clonal antibody 1:4000. The next day, excess primary antibodies were removed by several washing steps in TBST 
and HRP-conjugated secondary antibodies were applied to the membrane for 60 minutes, room temperature, at 
the following dilutions: anti-mouse 1:20000, anti-rabbit antibody 1:200000, in blocking buffer. The proteins were 
visualized on X-ray film after adding chemiluminescent substrate (Millipore Immobilon ECL substrate) to the 
membrane. Uncropped western blot photos are available online in Supplementary Data. Densitometry analyses 
were carried out on at least 3 independent western blots, using ImageJ 1.48v software. For densitometry purposes 
non-saturated bands were chosen. When different proteins could not be detected on the same film due to their 
different expression levels (i.e. Fig. 2a), different exposition times of the same membrane were used and the cor-
responding measured band densities below saturation were corrected for the ratio of the two exposition times as 
a rough estimate for comparison.
Phosphatidylinositol-dependent phospholipase-C (PI-PLC) treatment. Cells were seeded on 
24-well plates. After reaching confluence, the PI-PLC treatment was carried out according to the manufacturer’s 
protocol. Briefly: cells were washed twice in PBS and the plate with cells having only PBS or PBS with PI-PLC 
(1 unit/ml PI-PLC) was rocked gently for 30 minutes at 4 °C. The supernatant media were removed from the cells, 
and the PI-PLC treated and untreated cells were harvested from the plates by scraping and were processed for 
SDS-PAGE. Detection of Shadoo in the media was carried out, as follows: media of PI-PLC treated and untreated 
conditions were removed and supplemented with 1% Proteinase inhibitor cocktail, 1% Calpain inhibitor, 1 mM 
DTT. Total protein in the media samples was precipitated with trichloroacetic acid treatment (~6% final TCA 
concentration, 30 minutes on ice, followed by a 30 minute centrifugation at 9000 × g, 4 °C). The precipitated pro-
tein was resuspended in 1× loading dye and 20 μ l for each was loaded on gels.
Cell viability assays. Cells stably transfected or transduced were seeded onto 96-well plates at 3 * 104 cells/well 
density (SH-SY5Y cells). After the attachment of the cells, cells were treated by G418 by changing the medium 
to fresh containing serial dilutions of G418 and culturing the cells for additional 48 hours. After G418 treatment, 
the medium was replaced by PBS containing 5% PrestoBlue and cells were placed back into the CO2 incubator 
for additional 60 minutes before measuring fluorescence with a Perkin Elmer Viktor X3 2030 Multilabel Reader 
(excitation: 555 nm, emission: 585 nm).
Whole cell patch clamping. Whole cell recordings were performed using borosilicate patch pipettes 
(3–5 MΩ ). Cells were visualized with 40X objective using an Olympus BX51WI microscope equipped with 
reflected fluorescence as well as differential interference contrast observation systems. Experiments were con-
ducted at room temperature with the following solutions. Internal: 140 mM Cs-glucuronate, 5 mM CsCl, 4 mM 
MgATP, 1 mM Na2GTP, 10 mM EGTA, and 10 mM HEPES (pH 7.4 with CsOH); External: 150 mM NaCl, 4 mM 
KCl, 2 mM CaCl2, 2 mM MgCl2, 10 mM glucose, and 10 mM HEPES (pH 7.4 with NaOH). Data were acquired 
using a Multiclamp 700B amplifier and pClamp 10 software (Molecular Devices, Foster City, CA), and sampled at 
5 kHz with a Digidata 1440 (Molecular Devices, Foster City, CA).
Statistics. Cell viability assays were done with 5 parallel samples for every condition. The number of surviv-
ing cells in case of each drug concentration was normalized to the number of cells receiving no drug treatments. 
For statistical analysis, concentration of 250 μ g/ml G418 was chosen.
Statistical analysis (Normality tests, Student’s t-tests, One-way ANOVAs with two-tailed Dunnett’s or Tukey’s 
HSD post-hoc tests) was carried out on data from at least 3 independent experiments with SPSS Statistics v20 soft-
ware. On plots, mean ± standard deviation (SD) values are shown. p values: *0.01 < p < 0.05, **0.001 < p < 0.01, 
***p < 0.001.
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